CGN Nuclear Technology Development Valuation
Is 881 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 881 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 000881 (CN¥6.9) is trading below our estimate of fair value (CN¥16.32)
Significantly Below Fair Value: 000881 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 881?
Other financial metrics that can be useful for relative valuation.
What is 881's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | CN¥6.52b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 1.8x |
Enterprise Value/EBITDA | 20.6x |
PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 881's PS Ratio compare to its peers?
Company | Forward PS | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 3.9x | ||
603181 Zhejiang Huangma TechnologyLtd | 3.1x | 21.5% | CN¥6.2b |
300758 Anshan Hifichem | 4.6x | 13.9% | CN¥5.9b |
300429 Changzhou Tronly New Electronic Materials | 6.4x | n/a | CN¥5.3b |
002440 Zhejiang Runtu | 1.4x | 3.1% | CN¥7.5b |
000881 CGN Nuclear Technology Development | 1.3x | n/a | CN¥6.5b |
Price-To-Sales vs Peers: 000881 is good value based on its Price-To-Sales Ratio (1.3x) compared to the peer average (3.9x).
Price to Earnings Ratio vs Industry
How does 881's PE Ratio compare vs other companies in the CN Chemicals Industry?
Price-To-Sales vs Industry: 000881 is good value based on its Price-To-Sales Ratio (1.3x) compared to the CN Chemicals industry average (2.2x).
Price to Sales Ratio vs Fair Ratio
What is 881's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PS Ratio | 1.3x |
Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 000881's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.